8-fluoro-5-(4-fluorophenyl)-1,3,4,5-tetrahydro-1-benzazepin-2-one | 68351-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 8-fluoro-5-(4-fluorophenyl)-1,3,4,5-tetrahydro-1-benzazepin-2-one
• 英文别名: 8-Fluor-5-(4-fluorphenyl)-1,2,3,4-tetrahydro-1-benzazepin-2-on；8-fluoro-5-(4-fluoro-phenyl)-1,3,4,5-tetrahydro-benzo[b]azepin-2-one；8-fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1H-1-benzazepine-2-one
• CAS: 68351-37-1
• 化学式: C₁₆H₁₃F₂NO
• 分子量: 273.282
• InChiKey: VUBSWXMQODWBJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-fluoro-5-(4-fluorophenyl)-1,3,4,5-tetrahydro-1-benzazepin-2-one 在 lithium aluminium tetrahydride 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 8-fluoro-5-(4-fluorophenyl)-2,3,4,5-tetrahydro-1H-1-benzazepine
  参考文献：
  名称：

  EP1475368

  摘要：

  公开号：
• 作为产物：
  描述：

  (NE)-N-[7-fluoro-4-(4-fluorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene]hydroxylamine 以68%的产率得到
  参考文献：
  名称：

  VEJDELEK Z.; SVATEK E.; HOLUBEK J.; METYS J.; BARTOSOVA M.; PROTIVA M., COLLECT. CZECH CHEM. COMMUN., 1981, 46, NO 1, 148-160

  摘要：

  DOI：

文献信息

• Synthesis and pharmacological screening of 1-[2-tert-aminoethyl]-8-fluoro-5-[4-fluorophenyl]-2,3,4,5-tetrahydro-1H-1-benzazepines, their 1-[aminoacetyl] analogues and 1-substituted 9-fluoro-6-[4-fluorophenyl]-5,6-dihydro-4H-s-triazolo[4,3-a]-1-benzazepines
  作者：Zdeněk Vejdělek、Emil Svátek、Jiří Holubek、Jan Metyš、Marie Bartošová、Miroslav Protiva

  DOI：10.1135/cccc19810148

  日期：——

  7-Fluoro-4-(4-flurophenyl)-1-naphthylamine (III) was identified as a by-product in the transformation of 7-fluoro-4-(4-fluorophenyl)-1-tetralone oxime to the lactam I. Reaction of 8-fluoro-5-(4-flurophenyl)-2,3,4,5-tetrahydro-1H-1-benzazepine (V) with chloracetyl chloride gave the chloramide VI which was treated with secondary amines to give the aminoacetamides VII, VIII, XI and XII. reduction with lithium aluminium hydride afforded the amines IX, X, XIV and XV. Acylation of the piperazinoethanols XII and XV led to the esters XIII, XVI and XVII. Reaction of the lactam I with phosphorus pentasulfide gave the thiolactam II which was treated with a series of acid hydrazides and gave the title compounds XVIII-XXIV. Some of the compounds exhibited only in relatively high doses anticonvulsant and central depressant effects in various tests.

  7-氟-4-(4-氟苯基)-1-萘胺(III)被鉴定为7-氟-4-(4-氟苯基)-1-四酮肟转化为内酰胺I的副产物。8-氟-5-(4-氟苯基)-2,3,4,5-四氢-1H-1-苯并氮癸烷(V)与氯乙酰氯反应得到氯酰胺VI，然后用二级胺处理，得到氨基乙酰胺VII、VIII、XI和XII。用锂铝氢还原得到胺IX、X、XIV和XV。对哌嗪乙醇XII和XV进行酰化反应，得到酯XIII、XVI和XVII。将内酰胺I与五硫化二磷反应得到硫内酰胺II，再用一系列酸酐反应制备出标题化合物XVIII-XXIV。其中一些化合物在各种试验中仅在相对较高的剂量下表现出抗惊厥和中枢抑制作用。
• N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1475368A1

  公开（公告）日：2004-11-10

  The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.

  本发明涉及由式(I)表示的化合物（式(I)中的所有符号与说明书中的描述相同。 (其中式(I)中的所有符号与说明书中的描述含义相同。)、由该化合物组成的丝裂原苯并氮杂卓受体(MBR)拮抗剂、预防和/或治疗由压力引起的疾病的药物，其有效成分为该化合物。 由于式 (I) 所代表的化合物具有 MBR 拮抗活性，并能控制神经类固醇的产生，因此可用作预防和/或治疗由压力引起的疾病的药物。
• N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
  申请人：Seko Takuya

  公开号：US20050101600A1

  公开（公告）日：2005-05-12

  The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.

  本发明涉及由式(I)表示的化合物（式(I)中的所有符号与说明书中的描述相同。 (其中式(I)中的所有符号与说明书中的描述含义相同。)、由该化合物组成的丝裂原苯并氮杂卓受体(MBR)拮抗剂、预防和/或治疗由压力引起的疾病的药物，其有效成分为该化合物。由于式 (I) 所代表的化合物具有 MBR 拮抗活性，并能控制神经类固醇的产生，因此可用作预防和/或治疗由压力引起的疾病的药物。
• VEJDELEK, Z.;PROTIVA, M.;METYS, J.
  作者：VEJDELEK, Z.、PROTIVA, M.、METYS, J.

  DOI：——

  日期：——
• US7368444B2
  申请人：——

  公开号：US7368444B2

  公开（公告）日：2008-05-06